Wockhardt's Zaynich has achieved a historic milestone by becoming India's first New Chemical Entity (NCE) fully invented, developed, and commercialised by an Indian pharmaceutical company to receive FDA approval. The injectable drug, approved on May 30, 2026, combines Cefepime, a cephalosporin antibiotic, and Zidebactam, a new molecule that attacks different proteins, making Zaynich effective against multidrug-resistant, gram-negative bacteria. Unlike most antibiotics in its class, Zaynich attacks three bacterial proteins simultaneously, making it significantly harder for bacteria to develop resistance and creating an antibiotic that can kill drug-resistant bacteria for which doctors currently have almost no treatment.
Zidebactam is a 'new chemical entity (NCE)', defined as a molecule that did not exist before being created in the lab. As reported by Business Standard, it represents India's second FDA-approved NCE, with the first being Enmetazobactam invented by Orchid Pharma and licensed to a German biotech for commercialisation. The Drugs Controller General of India (DCGI) approved Zaynich in India on May 27, 2026, three days before the FDA approval, with a marketing application pending with the European Medicines Agency (EMA). The drug was developed by a multidisciplinary team of over 150 scientists led by researchers such as Mahesh Patel, with Habil Khorakiwala initiating and supporting the long-term antibiotic discovery program over nearly 15 years.
The Phase 3 results were striking, with Zaynich achieving an 89 percent composite cure rate against complicated urinary tract infections (UTIs) compared with 68.4 percent for meropenem, currently the last-resort antibiotic for such cases. The pivotal Phase 3 trial was conducted across 64 sites in the US, Europe, Latin America, China, and India in the ENHANCE-1 study. Zaynich targets difficult gram-negative organisms such as Escherichia coli (E. coli), Klebsiella pneumoniae, and Pseudomonas aeruginosa that may resist many existing antibiotics, with a shorter 3-day once-daily treatment regimen that differentiates it from many conventional macrolide courses. The discovery team comprised hundreds of researchers spanning chemistry, microbiology, and clinical pharmacology over more than a decade, with discovery taking about five years just to identify the molecule.
Wockhardt has invested around $800 million in R&D over the years, developing six antibiotic molecules so far. As reported by Business Standard, the company took a big gamble by focusing on antibiotics and is following up with an ambitious strategy of doing its own global marketing. The approval comes amid a critical global health emergency, with antimicrobial resistance (AMR) causing over 1.3 million deaths annually and contributing to five million more deaths. In the US alone, over 2.8 million resistant infections occur annually, killing more than 35,000 people. If other molecules win regulatory approval, it would position Wockhardt as a global leader in antibiotic research, filling a critical gap as global pharmaceutical giants have pulled back from antibiotic research.
The antibiotic R&D journey remains challenging, with rates of failure being high, with the odds of success being literally one in a million. According to Business Standard, only 15 innovative antibiotic molecules were seeking regulatory approval in 2023, with four approved since then, one under review, and 10 discontinued. The reluctance of global giants to enter antibiotic R&D has created opportunities for Indian companies like Wockhardt, with increasing focus on such high-risk research potentially propelling India's drug industry into a new phase of growth and innovation. Zaynich's success demonstrates that India built one of the world's great pharmaceutical industries on the back of generics, but originating a molecule entirely from scratch represents a new milestone for the country's pharmaceutical capabilities.
